Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Opinion: An 'Integrated Approach' To U.S. Global Health Aid; G8 Agriculture Investment
Global Health Aid Should Take An "Integrated Approach"
generic viagra online
Big Disparities In The Treatment Of Arrhythmias Across Europe
The latest statistics regarding the use of pacemakers and implantable cardiac devices in Europe was presented on Sunday 21 June, at EUROPACE 2009, the meeting of the European Heart Rhythm Association (EHRA)1 which takes place in Berlin, Germany from 21 to 24 June.
News of the day
Industry Lobby Wars Heighten As Reform Efforts Progress
"Healthcare companies are spending millions of dollars and marshaling armies of lobbyists to influence a landmark debate in the U.S. Congress that could dramatically change the way they do business," Reuters reports. "Drugmakers, doctors, insurers and hospitals have opened their wallets, spending more than $1 million a day to buy a voice in the escalating political battle over what could be the broadest revamp of healthcare laws in decades." And "as the debate has unfolded, key lawmakers have seen a surge in campaign donations, and hundreds of lobbyists have jammed Capitol hallways and lined the reception room outside the Senate chamber to talk to lawmakers." Sheila Krumholz, executive director of the Center for Responsive Politics, says "there is a frenzy going on to get in your two cents worth before the legislation reaches the next stage."
Sexual Health

Focusing On The More Lethal Form Of The Cancer Rhabdomyosarcoma

Rhabdomyosarcoma (RMS) is an aggressive muscle cancer that mostly affects children. The most common forms of RMS are embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS). Although ARMS is less common than ERMS, it is associated with a much higher rate of mortality. A therapy tailored to the ARMS form of RMS is therefore badly needed. A team of researchers, at the Hospital for Sick Children, Toronto, and Monash Institute of Medical Research, Australia, has now provided hope that it might be possible to develop such a therapy by showing that the protein ILK promotes the growth of ARMS cells, whereas it suppresses the growth of ERMS cells. The team, led by David Malkin and Gregory Hannigan, determined that the signaling protein JNK mediated these differing effects of ILK. Knocking down expression of ILK in ERMS cells induced activation of JNK and promoted tumor cell growth both in vitro and when the cells were transplanted into immunodeficient mice. Conversely, knocking down expression of ILK in ARMS cells abrogated both JNK signaling and tumor cell growth. Further analysis revealed that the protein product of the fusion gene that characterizes ARMS downregulated JNK1 expression, providing mechanistic insight into the opposing roles of ILK in ARMS and ERMS. The authors therefore suggest it should be possible to identify patients with ARMS who would benefit from an anticancer therapeutic that targets ILK. In an accompanying commentary, Charles Keller and colleagues concur with the authors that targeting ILK might provide a therapeutic strategy tailored to the treatment of ARMS. However, they caution that further studies are needed, in part because of the high rate of misdiagnosis of ARMS versus ERMS. TITLE: JNK1 determines the oncogenic or tumorsuppressive activity of the integrin-linked kinase in human rhabdomyosarcoma AUTHOR CONTACT: David Malkin Hospital for Sick Children, Toronto, Ontario, Canada. Gregory E. Hannigan Monash Institute of Medical Research, Melbourne, Victoria, Australia. ACCOMPANYING COMMENTARY TITLE: Integrin-linked kinase: both Jekyll and Hyde in rhabdomyosarcoma AUTHOR CONTACT: Charles Keller University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA. Karen Honey Journal of Clinical Investigation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009